ICAD Stock

ICAD

US44934S2068

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 16:00:00 2025-07-16 EDT			5-day change	1st Jan Change
3.870 ^USD	+3.75%		-.--%	-

25-07-20	ICAD, Inc.(NasdaqCM:ICAD) dropped from S&P TMI Index	CI
25-07-17	ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell Microcap Value Benchmark Index	CI

Analysts' recommendations: ICAD

25-04-17	RadNet's iCAD Deal to Expand its Digital Health Services and Geographic Presence, Truist Says	MT
25-04-17	BTIG Research Downgrades iCAD to Neutral From Buy	MT
23-07-19	Lake Street Adjusts Price Target on icad to $5 From $2.50, Maintains Buy Rating	MT
23-04-13	JMP Securities Adjusts iCAD's Price Target to $4 From $7, Keeps Outperform Rating	MT
23-04-04	Oppenheimer Adjusts iCAD Price Target to $4 From $5, Maintains Outperform Rating	MT

More recommendations

iCAD Inc is a United Statesâ€‘based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AIâ€‘driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement and Estimates

More financial data

Stock Market
Stocks
ICAD Stock

As early as today, start finding the best investment opportunities!

Market Cap	106M 91.49M 85.72M 78.18M 147M 10.07B 149M 1.01B 394M 5.04B 396M 388M 16.82B	P/E 2023	-9.35x	P/E 2024	-8.59x
Enterprise Value	88.75M 76.89M 72.04M 65.71M 124M 8.46B 125M 847M 331M 4.24B 333M 326M 14.13B	EV / Sales 2023	1.47x	EV / Sales 2024	1.6x
Free-Float	99.32%	Yield 2023 *	-	Yield 2024	-

25-07-08	ICAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by RadNet, Inc.	AQ
25-06-03	ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD	BU
25-05-13	ICAD Reports Financial Results for First Quarter Ended March 31, 2025	AQ
25-04-29	ICAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft’s Precision Imaging Network (PIN)	AQ
25-04-17	ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD	BU

23-03-13	LA PREMIÈRE ÉTAPE DE L’OPÉRATION CONSISTE EN LA CESSION PAR ICAD…
21-04-26	CAC 40 : Les valeurs à suivre à Paris et en Europe
21-04-26	Les valeurs à suivre à Paris et en Europe (actualisé)
19-10-18	ICAD : annonce l’installation de la solution ProFound AI™ 2D pour la mammographie et pour la tomosynthèse (DBT) 3D au Centre d’Imagerie Paris Nord Sarcelles
19-01-25	Dow Jones Industrial Average : Wall Street attendue en hausse malgré Intel et les doutes sur la croissance

3 years	1.18	4.02
5 years	1.05	12.73
10 years	1.05	21.44

Manager	Title	Age	Since
Dana Brown CEO	Chief Executive Officer	61	2023-03-09
Mark Stolper DFI	Director of Finance/CFO	54	2025-07-16
Dave Katz SEC	Corporate Secretary	-	2025-07-16

ICAD Stock

Stocks

ICAD

US44934S2068

Advanced Medical Equipment & Technology

Valuation: ICAD

Latest news : ICAD

Analysts' recommendations: ICAD

Press Releases: ICAD

News in other languages: ICAD

Quotes and Performance

Course Extremes

Managers and Directors: ICAD

Latest insider transactions

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Income Statement and Estimates

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/17/25	Andrew Sassine	Issuer sale	Director	1,553,657	5.8540%
7/17/25	Eric Lonnqvist	Issuer sale	Chief Financial Officer	158,488	0.5972%
7/17/25	Jonathan Go	Issuer sale	Chief Technology Officer	351,145	1.3231%

	2023	2024
Net sales	17.32M 15M 14.06M 12.82M 24.11M 1.65B 24.48M 165M 64.63M 827M 65.02M 63.61M 2.76B	19.61M 16.99M 15.92M 14.52M 27.29M 1.87B 27.71M 187M 73.18M 936M 73.62M 72.02M 3.12B
Net income	-4.85M -4.2M -3.93M -3.59M -6.75M -462M -6.85M -46.28M -18.09M -231M -18.2M -17.8M -772M	-5.62M -4.87M -4.56M -4.16M -7.82M -536M -7.94M -53.62M -20.96M -268M -21.09M -20.63M -894M
Net Debt	-21.21M -18.38M -17.22M -15.7M -29.52M -2.02B -29.98M -202M -79.15M -1.01B -79.63M -77.9M -3.38B	-16.84M -14.59M -13.67M -12.47M -23.45M -1.61B -23.81M -161M -62.86M -804M -63.24M -61.87M -2.68B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ICAD	+3.75%	-.--%	-.--%	+51.17%	106M
THERMO FISHER SCIENTIFIC, INC.	-0.33%	+4.36%	+26.31%	+11.60%	224B
DANAHER CORPORATION	-0.80%	+3.07%	+0.03%	-19.98%	146B
INTUITIVE SURGICAL, INC.	+0.01%	+6.95%	-16.09%	+31.53%	142B
BOSTON SCIENTIFIC CORPORATION	+0.45%	+7.71%	-49.90%	+0.18%	74.19B
EDWARDS LIFESCIENCES CORPORATION	-0.65%	+4.59%	+20.95%	+15.55%	53.99B
SIEMENS HEALTHINEERS AG	-1.41%	+0.08%	-14.95%	-17.29%	50.85B
AGILENT TECHNOLOGIES, INC.	-0.84%	+5.05%	+26.36%	+17.05%	42.22B
WATERS CORPORATION	+0.28%	+4.04%	+45.75%	+44.31%	40.75B
GE HEALTHCARE TECHNOLOGIES INC.	-0.65%	+2.90%	-2.86%	+0.67%	32.86B
Average	-0.15%	+4.77%	+3.56%	+13.48%	80.62B
Weighted average by Cap.	-0.58%	+6.23%	+3.92%	+8.28%